Pharmacokinetics of lactone, carboxylate and total 9-nitro-camptothecin with different doses and administration routes in rats

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 2, 2006, Pages 53-59

  Chen, Jun ^a   Ping, Qineng ^a   Guo, Jianxin ^a   Chu, Xiaozhu ^a   Song, Mingmei ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

9 nitrocamptothecin; Lactone; Pharmacokinetics; Rats; Total

Indexed keywords

CARBOXYLIC ACID; LACTONE; RUBITECAN;

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; MALE; NONHUMAN; RAT; RAT STRAIN; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CAMPTOTHECIN; CARBOXYLIC ACIDS; INJECTIONS, INTRAVENOUS; LACTONES; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33645322942     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.480     Document Type: Article

References (12)

1. Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-720.
2. Giovanella BC, Hinz HR, Kozielski AJ, et al. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(s)-camptothecin. Cancer Res 1991; 51: 3052-3055.
3. Giovanella BC, Stehlin JS, Hinz HR, et al. Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(s)-camptothecin (Rubitecan). Int J Oncol 2002; 20: 81-88.
4. Hung CL, Doniger J, Palini A, et al. 9-Nitrocamptothecin inhibits HIV-1 replication in human peripheral blood lymphocytes: a potential alternative for HIV-infection/AIDS therapy. J Med Virol 2001; 64: 238-244.
5. Stehlin JS, Giovanella BC, Natelson EA, et al. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int J Oncol 1999; 14: 821-831.
6. Cao Z, Harris N, Kozielski A, et al. Alkyl esters of camptothecin and 9-nitrocamptothecin: synthesis, in vitro pharmacokinetics, toxicity and antitumor activity. J Med Chem 1998; 41: 31-37.
7. Zhang R, Li Y, Cai Q, et al. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I. Cancer Chemother Pharmacol 1998; 41: 257-267.
8. Zhong DF, Li K, Xu JH, et al. Pharmacokinetics of 9-nitro-20(s)-camptothecin in rats. Acta Pharmcol Sin 2003; 24: 256-262.
9. Chow DS, Gong L, Wolfe MD, et al. Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin. Ann NY Acad Sci 2000; 922: 164-174.
10. Scott DO, Bindra DS, Stella VJ. Plasma pharmacokinetics of the lactone and carboxylate forms of 20(s)-camptothecin in anesthetized rats. Pharm Res 1993; 10: 1451-1457.
11. Warner DL, Burke TG. Simple and versatile high-performance liquid chromatographic method for the simultaneous quantitation of the lactone and carboxylate forms of camptothecin anticancer drugs. J Chromatogr B 1997; 691: 161-171.
12. Sha X, Fang X. Transport characteristics of 9-nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Int J Pharm 2004; 272: 161-171.